Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $30.00 at Wells Fargo & Company

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective dropped by equities researchers at Wells Fargo & Company from $34.00 to $30.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 35.29% from the company’s current price.

A number of other equities research analysts have also commented on the stock. Zacks Research lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Needham & Company LLC lowered their price objective on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Finally, Barclays began coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $29.50.

Amphastar Pharmaceuticals Trading Down 16.3%

AMPH traded down $4.32 on Friday, hitting $22.17. 551,978 shares of the company were exchanged, compared to its average volume of 359,782. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.21 and a current ratio of 3.12. The firm has a fifty day simple moving average of $27.36 and a two-hundred day simple moving average of $27.06. The stock has a market capitalization of $1.02 billion, a PE ratio of 9.90, a price-to-earnings-growth ratio of 5.10 and a beta of 0.88. Amphastar Pharmaceuticals has a 12 month low of $20.39 and a 12 month high of $31.26.

Insider Activity at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 2,426 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $25.92, for a total value of $62,881.92. Following the sale, the director directly owned 71,368 shares of the company’s stock, valued at $1,849,858.56. This represents a 3.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rong Zhou sold 9,787 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total transaction of $256,419.40. Following the transaction, the executive vice president directly owned 138,043 shares of the company’s stock, valued at $3,616,726.60. This represents a 6.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 13,950 shares of company stock worth $363,925 over the last 90 days. 27.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 356.0% in the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after buying an additional 737 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $26,000. Global Retirement Partners LLC lifted its position in Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after acquiring an additional 703 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Amphastar Pharmaceuticals by 3,430.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after purchasing an additional 1,338 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $32,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals News Roundup

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Management outlined mid‑ to high‑single‑digit revenue growth for 2026 and is launching a new respiratory product, which supports future organic growth expectations. Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
• Positive Sentiment: Needham cut its price target from $34 to $30 but kept a “buy” rating — the revision reduces expected upside but signals continued analyst confidence in the company’s longer‑term prospects. Benzinga
• Neutral Sentiment: Amphastar released full Q4 2025 and FY results: Q4 net revenue ~$183.1M (FY ~$719.9M); GAAP and adjusted reporting differ ($0.51 GAAP Q4 / $0.73 adjusted Q4 EPS), and the company provided prepared remarks on the quarter. These filings provide detail but mixed signals for near‑term momentum. Amphastar Reports Financial Results
• Neutral Sentiment: Earnings call transcript and highlights are available for investors who want management commentary on sales drivers, margins, and pipeline timing (useful for modeling). Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed Street expectations: adjusted EPS $0.73 vs. consensus ~$0.97 and revenue also missed estimates — the misses are the primary catalyst for the share decline today. Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Market writeups noted the revenue miss prompted the selloff; investors likely reacted to both the earnings shortfall and lower near‑term visibility despite positive guidance for 2026. Yahoo: Amphastar Misses Q4 Revenue Estimates
• Neutral Sentiment: Reported short‑interest data appears inconsistent in public feeds (showing zero shares); investors should treat those short‑interest figures as unreliable until clarified by official filings.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.